<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">29551533</PMID>        <DateRevised>            <Year>2018</Year>            <Month>04</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-114X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>40</Volume>                    <Issue>4</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Apr</Month>                    </PubDate>                </JournalIssue>                <Title>Clinical therapeutics</Title>                <ISOAbbreviation>Clin Ther</ISOAbbreviation>            </Journal>            <ArticleTitle>Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.</ArticleTitle>            <Pagination>                <MedlinePgn>574-586.e4</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0149-2918(18)30062-6</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2018.02.012</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The SQ tree sublingual immunotherapy (SLIT)-tablet containing allergen extracts with the major allergen Bet v 1 from birch pollen is currently being developed for the treatment of tree pollen-induced allergic rhinitis/conjunctivitis with or without asthma. The aim of this Phase II trial was to investigate the dose-related efficacy and safety of the SQ tree SLIT-tablet.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This study was a randomized, parallel-group, double-blind, placebo-controlled, multi-national trial conducted in Europe. A total of 637 participants were randomized equally to receive placebo or treatment with the SQ tree SLIT-tablet in doses of 0.5, 1, 2, 4, 7, or 12 development units (DU). Treatment was initiated ~16 weeks before onset of the 2013 birch pollen season (BPS) and was continued throughout the BPS with a total duration of at least 6 months. During the BPS and tree pollen season (TPS), subjects assessed rhinoconjunctivitis symptoms and medication use on a daily basis in an electronic diary; weekly assessments of rhinoconjunctivitis quality of life were also made.</AbstractText>                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Analysis of the average daily symptom score during the BPS and the TPS showed that the difference between active treatment and placebo was statistically significant for the 7 DU group (BPS, P = 0.02; TPS, P = 0.03), with no clear dose-response relationship. All doses of the SQ tree SLIT-tablet induced changes from baseline in birch-specific IgE and IgG<sub>4</sub> that were statistically significant compared with placebo at all time points assessed (P &lt; 0.0001) with a clear dose-response relationship for birch specific IgG<sub>4</sub>. In general, the SQ tree SLIT-tablet was well tolerated, with the majority of treatment-related adverse events (≥95%) being mild or moderate in severity. The most frequently reported treatment-related adverse events were generally related to the sublingual administration of the tablet (ie, they occurred in the oral cavity).</AbstractText>                <AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">The results from this trial suggest that the SQ tree SLIT-tablet in doses up to 12 DU has a tolerability profile suitable for at-home administration. The immunomodulatory changes indicate a dose-response relationship, but clinical efficacy parameters were inconclusive, probably due to low pollen counts, emphasizing the importance of pollen exposure for the outcome of a pollen allergy immunotherapy trial. EudraCT no: 2012-000031-59.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier HS Journals, Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mäkelä</LastName>                    <ForeName>Mika J</ForeName>                    <Initials>MJ</Initials>                    <AffiliationInfo>                        <Affiliation>Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gyllfors</LastName>                    <ForeName>Pär</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Asthma &amp; Allergy Department, St. Göran's Hospital, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Valovirta</LastName>                    <ForeName>Erkka</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland; Terveystalo Allergy Clinic, Helsinki, Finland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Steffensen</LastName>                    <ForeName>Maria A</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>Global Research &amp; Development, ALK, Hørsholm, Denmark. Electronic address: mafdk@alk.net.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Grønager</LastName>                    <ForeName>Pernille M</ForeName>                    <Initials>PM</Initials>                    <AffiliationInfo>                        <Affiliation>Global Research &amp; Development, ALK, Hørsholm, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Savolainen</LastName>                    <ForeName>Johannes</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Winther</LastName>                    <ForeName>Lone</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Dermato-Allergology, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>03</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Ther</MedlineTA>            <NlmUniqueID>7706726</NlmUniqueID>            <ISSNLinking>0149-2918</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">allergic rhinoconjunctivitis</Keyword>            <Keyword MajorTopicYN="N">birch pollen</Keyword>            <Keyword MajorTopicYN="N">clinical efficacy</Keyword>            <Keyword MajorTopicYN="N">immunology</Keyword>            <Keyword MajorTopicYN="N">sublingual immunotherapy tablet</Keyword>            <Keyword MajorTopicYN="N">tolerability</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>12</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>02</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>02</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>3</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>3</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>3</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">29551533</ArticleId>            <ArticleId IdType="pii">S0149-2918(18)30062-6</ArticleId>            <ArticleId IdType="doi">10.1016/j.clinthera.2018.02.012</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>